HIMS rebounds on GLP-1 growth and rising earnings estimates, while DXC slumps amid falling sales and eroding investor ...

We came across a bearish thesis on Hims & Hers on FJ Research’s Substack. As of 3ʳᵈ July, Hims & Hers’s share was trading at ...

Hims & Hers Health reports 111% Q1 2025 revenue growth to $586M, driven by personalized treatments & strong margins. Read why ...

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS ) between April 29, 2025 and June 23, 2025, both dates inclusive (the ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

The market for generic GLP-1 weight loss drugs in Canada is set to open up, and Hims & Hers is ready to jump in.  | Novo ...

We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Hims & Hers Health, Inc. (NYSE:HIMS) is one of the stocks Jim Cramer recently discussed. Hims & Hers ...

Investing.com -- Hims & Hers CEO Andrew Dudum has shared new information about the company’s terminated partnership with Novo Nordisk (NYSE: NVO ), which ended in June 2025, in an interview with The ...

On June 25, 2025, two securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of ...

Hims & Hers, the high-flying online health company that rapidly grew from a buzzy startup selling Viagra to a ...

Hims & Hers stands out for personalized, compounded medications and consistent margin expansion but faces rising risks tied ...